It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Recently it has become possible to de novo design high affinity protein binding proteins from target structural information alone. There is, however, considerable room for improvement as the overall design success rate is low. Here, we explore the augmentation of energy-based protein binder design using deep learning. We find that using AlphaFold2 or RoseTTAFold to assess the probability that a designed sequence adopts the designed monomer structure, and the probability that this structure binds the target as designed, increases design success rates nearly 10-fold. We find further that sequence design using ProteinMPNN rather than Rosetta considerably increases computational efficiency.
Recently, a pipeline for the design of protein-binding proteins using only the structure of the target protein was reported. Here, the authors report that the incorporation of deep learning methods into the original pipeline increases experimental success rate by ten-fold.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 University of Washington, Department of Biochemistry, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); University of Washington, Institute for Protein Design, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); University of Washington, Molecular Engineering Graduate Program, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
2 University of Washington, Department of Biochemistry, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); University of Washington, Institute for Protein Design, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); University of Washington, Howard Hughes Medical Institute, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
3 University of Washington, Department of Biochemistry, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); University of Washington, Institute for Protein Design, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
4 University of Washington, Department of Biochemistry, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); University of Washington, Institute for Protein Design, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); University of Washington, Department of Bioengineering, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
5 VIB-UGent Center for Inflammation Research, Ghent, Belgium (GRID:grid.510970.a); Ghent University, Unit for Structural Biology, Department of Biochemistry and Microbiology, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798)